Symphogen A/S to Present Rozrolimupab (SYM001) Data at European Hematology Association Meeting
6/2/2011 11:06:16 AM
Symphogen announced today that Phase 2 data will be presented from an open-label, multi-center clinical trial evaluating the safety and tolerability of rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP) at the 16th Congress of the European Hematology Association meeting (http://eha.eurocongres.com/16th/) in London, UK on June 10 from 5:45 to 7:00 PM. Preliminary results will be presented in a poster entitled “Phase II results of the first-in-class anti-RhD antibody mixture, rozrolimupab in primary immune thrombocytopenia (ITP)” by professor Tadeusz Robak of University of Lodz, Poland at the Immune Thrombocytopenia Poster Session.
comments powered by